BMY Bristol Myers Squibb Loading...

From JNJ earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
08:30
Jan 21 ◎
Jennifer Talbot Executive Vice President, Worldwide Chairman, Innovative Me… JNJ Q4 FY25 call
JNJ's partnership with BMS on milvexian (factor XIa inhibitor) may yield a $5B+ asset if pivotal data in AFib and secondary stroke are positive; JNJ's confidence in the collaboration suggests BMS shares development risk and upside.
BMY
HIGH

About BMY Analyst Coverage

Buzzberg tracks BMY (Bristol Myers Squibb) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Jennifer Talbot.